Institut für Medizinische Statistik - UMG

Dr. Markus Harden

Wissenschaftlicher Mitarbeiter - AG Klinische Studien
Humboldtallee 32, Erdgeschoss 0.136


[seit 07/2012] Wissenschaftlicher Mitarbeiter
Institut für Medizinische Statistik,
Universitätsmedizin Göttingen
[04/2013-04/2020] Promotion Dr. sc. hum.,
Georg-August-Universität Göttingen
[2006 - 2012] Studium der Mathematik mit Nebenfach Volkswirtschaftslehre
an der Georg-August-Universität Göttingen
[1987] Geboren in Wilhelmshaven


Statistik in der Medizin
Statistische Methoden des Drug Monitoring
Hochdimensionale Daten


Back schools for low back pain;
in collaboration with Prof. Sebastian Straube (Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton, Canada);
Funded by: the Federal Ministry of Education and Research (BMBF); Project duration: 2014-2015.

Biomarker driven individualized immunosuppression after liver transplantation;
in collaboration with Prof. Jürgen Brockmöller (PI, Dept. Clinical Pharmacology); Funded by: the Federal Ministry of Education and Research (BMBF); Project duration: 2012-2015.

Biostatistical Methods for Efficient Evaluation of Individualized Therapies (BIMIT);
in collaboration with the University Heidelberg, University Bremen and pharmaceutical industries;
PIs: Prof Meinhard Kieser (project coordinator), Institute of Medical Biometry and Informatics of the University Heidelberg; Prof Werner Brannath, Competence Center for Clinical Trials of the University Bremen and Prof Tim Friede, Department of Medical Statistics of the University Medical Center Göttingen;
Funded by: the Federal Ministry of Education and Research (BMBF); Project duration: 2013-2016.

EARLY PRO-TECT Alport: Early Prospective Therapy Trial to Delay Renal Failure in Children with Alport Syndrome (funded by BMBF)
Collaboration with the Department of Nephrology and Rheumatology; PI: Prof Oliver Gross, Department of Nephrology and Rheumatology, University Medical Center Göttingen; Project duration: 2011-2018.

EU-CERT-ICD - Comparative Effectiveness Research to Assess the Use of Primary Prophylactic Implantable Cardioverter Defibrillators in Europe;
Consortium of 19 European organisations; Consortium coordinator: Prof Markus Zabel from the Heart Center of the University Medical Center Göttingen
Funded by: the European Commision (EC); Project duration: 2013-2017.

TransValid B-KFO179/GRCSG-Trial: Preoperative radiochemotherapy combined with 5-fluorouracil and oxaliplatin followed by 3 cycles of FOLFOX chemotherapy ant total mesorectal excision in advanced rectal cancer (funded by DFG) Collaboration with the Department of General, Visceral and Pediatric Surgery; PI: Prof. Torsten Liersch and Prof Michael Ghadimi; Department of General and Visceral Surgery, University Medical Center Göttingen



[1] Bachelorthesis: Das nichtparametrische Behrens-Fisher-Problem mit Approximation nach Atiqullah (2009)
[2] Masterthesis: Das Behrens-Fisher-Problem für hochdimensionale Split-Plot-Designs (2012)
[3] Dissertation: Planung multizentrischer randomisierter klinischer Studien mit kontinuierlichem Endpunkt (2020)


[1] KSFE 2013, Ulm: Das Behrens-Fisher-Problem für hochdimensionale Split-Plot-Designs.
[2] Doktorandentreffen Stochastik 2013, Göttingen: Adaptive Behandlungsstrategien für Therapeutisches Drug Monitoring.
[3] ISCB 2013, München: Adaptive treatment designs for dose adjustments in immunosuppression.
[4] Biometrisches Kolloquium 2014, Bremen: Construction of target ranges in transplantation data.
[5] 60. GMDS-Jahrestagung 2015, Krefeld: Reporting of preferred study outcomes in randomized controlled trials of back schools for chronic low back pain - systematic review and meta-analysis.
[6] CEN ISBS 2017, Wien: Sample size estimation in multi-centre trials.
[7] DAGStat 2019, München: Blinded sample size recalculation in multi-centre clinical trials.


[1] ISCB 2014, Wien: Calculation of target range values on a continuous scale in immunosuppression following solid organ transplantation


[1] Harden M. (2013). Das Behrens-Fisher-Problem für hochdimensionale Split-Plot-Designs. [Open Access]
[2] Krasnianski et al. (2015). Psychiatric symptoms in patients with sporadic Creutzfeldt-Jakob disease in Germany. The Journal of Clinical Psychiatry, 76(9), 1209-1215. [DOI]
[3] Straube et al. (2016). Back schools for the treatment of chronic low back pain: possibility of benefit but no convincing evidence after 47 years of research-systematic review and meta-analysis. Pain. [DOI]
[4] Wetz et al. (2016). Unexpectedly high incidence of hypothermia before induction of anesthesia in elective surgical patients. Journal of Clinical Anesthesia, 34, 282-289. [DOI]
[5] Balcarek et al. (2016). Results of medial patellofemoral ligament reconstruction compared with trochleoplasty plus individual extensor apparatus balancing in patellar instability caused by severe trochlear dysplasia: a systematic review and meta-analysis. Knee Surgery, Sports Traumatology, Arthroscopy, 1-9. [DOI]
[6] Schütz et al. (2017). Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Medicine, 14(4), e1002286. [DOI]
[7] Grimmsmann et al. (2018). The influence of hospitalisation on the initiation, continuation and discontinuation of benzodiazepines and Z-drugs–an observational study. Swiss Medical Weekly, 148, w14590-w14590. [DOI]
[8] Harden and Friede. "Sample size calculation in multi-centre clinical trials." BMC Medical Research Methodology 18.1 (2018): 156. [DOI]
[9] Ott et al. "Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity." Journal of Neuroinflammation 16.1 (2019): 49. [DOI]
[10] Bauer et al. "Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study." The Lancet (2019). [DOI]
[11] Zabel et al. "Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project." Journal of Electrocardiology (2019). [DOI]
[12] Junttila et al. "Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators" Diabetes Care, (2020). [DOI]
[13] Gross et al. "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome." Kidney International, (2020). [DOI]
[14] Harden and Friede. "Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data." Biometrical Journal (2020). [DOI]